Abstract:
본 발명은 페닐프로파노이드 화합물에 관한 것으로서, 악취에 대해 소취효과를 가진 화합물을 제공하며, 하기 화학식 1로 표시되는 화합물을 제공한다. 하기 화학식 1에서, R 1 , R 2 , R 3 , R 4 및 R 5 는 각각 독립적으로 수소 원자, 탄소수 1~4의 알킬기, 탄소수 1~4의 아실기 및 하기 화학식 2로 표시되는 기로 이루어진 군으로부터 임의로 선택되고, R 6 은 수소 원자, 탄소수 1~4의 알킬기, 탄소수 1~4의 아실기, 탄소수 1~4의 아실옥시기, 탄소수 2~4의 알케닐기, 탄소수 1~4의 알데히드기 및 화학식 3으로 표시되는 기로 이루어진 군으로부터 임의로 선택되고, R 7 은 수소 원자, 탄소수 1~4의 알콕시기, 탄소수 1~4의 아실기, 탄소수 1~4의 아실옥시기 및 화학식 3으로 표시되는 기로 이루어진 군으로부터 임의로 선택되고, R 8 , R 9 및 R 10 은 각각 독립적으로 수소 원자, 탄소수 1~4의 알킬기 및 탄소수 1~4의 아실기로 이루어진 군으로부터 임의로 선택되고, 및 R 11 은 각각 독립적으로 수소 원자, 탄소수 1~4의 알콕시기, 탄소수 1~4의 아실기 및 탄소수 1~4의 아실옥시기로 이루어진 군으로부터 임의로 선택되는 것을 특징으로 한다: (화학식 1)
Abstract:
This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
Abstract:
4-Aminopicolinic acids having tri-and tetra-substituted aryl substituents in the 6-position, and their amine and acid derivatives, are potent herbicides demonstrating a broad spectrum of weed control.
Abstract:
[Chemical formula 1] (I) (wherein, for example, X represents hydrogen or halogeno; R1 represents hydrogen; R2 represents hydrogen or C1-4 alkyl; R3 represents -CHO or -COOH; and R4 represents -CH=CH-(CH2)p-CH3 (wherein p is an integer of 1 to 12), -CH(OH)-(CH2)q- CH3 (wherein q is an integer of 1 to 13), -CH(OH)-CH2- CH(CH3)-(CH2)2-CH=C(CH3)2, - CH=CH-CH(CH3)-(CH2)3-CH(CH3)2, -(CH2)2-CH(CH3)-(CH2)3- CH(CH3)2, or -(CH2)8-CH3), optical isomers of these, and pharmaceutically acceptable salts of these. These compounds have antitrypanosoma activity and are hence useful as a drug for the prevention of or treatments for diseases caused by trypanosome.
Abstract:
This invention provides a novel group of diphenyl ethene derivatives, pharmaceutically acceptable salts thereof, the process of making these compounds, their pharmaceutical composition and the use of these compounds as agents for treating immune, inflammatory and auto-immune diseases.
Abstract:
본 발명은 화학식 I의 화합물 또는 (프로드러그를 비롯한) 이것의 약학적으로 허용 가능한 유도체를 제공하며, 상기 화합물 및 유도체는, 예를 들면 특히 트롬빈의 억제가 요구되는 증상(예를 들면, 혈전증)의 처치에서 트립신 유사 프로테아제, 예컨대 트롬빈의 경쟁적인 억제제로서 또는 그 프로드러그로서 유용하거나, 또는 항응고제로서 또는 그 프로드러그로서 유용하다.
Abstract:
본 발명은 R a , R 1 , R 2 , Y 및 R 3 이 본 명세서의 정의를 갖는 화학식 I의 화합물 및 이의 약학적으로 허용 가능한 유도체(프로드러그를 포함함)를 제공하며, 이 화합물 및 유도체는 트립신계 세린 프로테아제, 예컨대 트롬빈의 경쟁적 억제제로서 유용하거나 이 억제제의 프로드러그로서 유용하므로, 특히 트롬빈의 억제가 필요한 상태의 치료에서 또는 항응고제로서 유용하다.
Abstract:
PURPOSE: Provided are a fluorene based compound having various functional groups, which can be applied as electroluminescence material, and other optoelectronic material, a polymer thereof, and an electroluminescence device using the same as illuminant. CONSTITUTION: The fluorene based compound is represented by formula 1. In the formula 1, R represents hydrogen, an aliphatic or alicyclic alkyl or alkoxy group having C1-C22, aryl or aryloxy group having C6-C18, or alkyl or aryl derivatives such as silicon, tin, or germanium, R' represents a functional group positioned in meta or para position of phenyl group, which is optionally selected from the group consisting of ether, ester, amine, amide, aldehyde, ketone, sulfone, sulfide, nitro, nitrile, acetylene, halogen, carboxylic acid, boric acid, vinyl, hydrazide, isocyanate, urethane, carbonate, chloromethyl, hydroxy, anhydride, cyanate, azomethine, quinoline, oxadiazole, and azo groups, and n is 0 or 1.
Abstract:
PURPOSE: Provided are a ferulic acid dimer, a pharmaceutically acceptable salt thereof, a method for preparing the same, its use in treating dementia, and an intermediate of the ferulic acid dimer. CONSTITUTION: The ferulic acid dimer is represented by formula 1. In the formula 1, X is carbon, oxygen or nitrogen, and n is 0-3. The salt of the ferulic acid dimer is an inorganic salt including sodium salt, potassium salt, magnesium salt, and calcium salt, or an organic salt including angelic acid, ricin, ethanolamine, N,N'-dibenzylethylene diamine, and alpha-tocopherol. The method comprises reacting a hydroxybenzaldehyde compound of formula 2(wherein X is carbon, oxygen or nitrogen, and n is 0-3) with malonic acid to form the ferulic acid dimer of formula 1.
Abstract:
PURPOSE: Novel naphtha compounds, pharmaceutical formulations thereof, and methods of using such compounds for the treatment of postmenopausal syndrome and other estrogen-related pathological conditions are provided. The new pharmaceutical agents are capable of alleviating the symptoms of, inter alia, postmenopausal syndrome. CONSTITUTION: The novel naphthyl compounds have the formula wherein R1 is -H, -OH,-O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R2 is -H, -F, -Cl, -OH, -O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R3 and R4 are, independently, -H, -F, -Cl, -CH3, -OH,-O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or-OSO2(C4-C6 alkyl), with the proviso that both R3 and R4 cannot be hydrogen; n is 2 or 3; and R5 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethyl amino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt or solvate thereof.